$CRDF SEC Filings

Filed On	Filing
27 Oct 2026	Form 3: Alland Leila, Chief Medical Officer No securities owned
27 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year +1 more Date of Report (Date of earliest event reported): October 22, 2026
22 Oct 2026	8-K: Submission of Matters to a Vote of Security Holders On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of common stock, constituting a quorum, were represented in person or by valid pro...
14 Sep 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
26 Aug 2026	DEFA14A
26 Aug 2026	Proxy statement: special meeting on October 22, 2026
14 Aug 2026	PRE 14A
11 Aug 2026	10-Q
11 Aug 2026	8-K: Results of Operations and Financial Condition
27 Jul 2026	SCHEDULE 13G/A
21 Jul 2026	S-8
16 Jul 2026	Form 4: Pace Gary W, Director Bought 687,285 shares ($1M) · Acquired 687,285 Common Stock Purchase Warrant (Open Market Purchase)
16 Jul 2026	Form 4: Mohindru Mani, Director Bought 34,364 shares ($50K) · Acquired 34,364 Common Stock Purchase Warrant (Open Market Purchase)
16 Jul 2026	424B5
16 Jul 2026	8-K: Entry into a Material Definitive Agreement; Other Events
22 Jun 2026	Form 4: Mohindru Mani, Director Bought 24,703 shares ($29.9K)
22 Jun 2026	Form 4: Pace Gary W, Director Bought 30,000 shares ($36.6K)
15 Jun 2026	Form 4: Armitage James O, Director Granted 40,565 Stock Options
15 Jun 2026	Form 4: White Lale, Director Granted 40,565 Stock Options
15 Jun 2026	Form 4: Tannenbaum Renee P, Director Granted 40,565 Stock Options

Comments